Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-01
2007-05-01
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S171000, C514S249000, C514S603000, C514S678000
Reexamination Certificate
active
10667208
ABSTRACT:
The present invention provides a therapeutic method to treat non-malignant diseases characterized by the excessive tissue growth, e.g., hyperplastic diseases, comprising administering to a mammal (e.g., human) afflicted with excessive tissue growth, an effective amount of a derivative of an indole compound of formula (I):formula (I):wherein R1is lower alkyl, (hydroxy)lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl or 2-thienyl; R2, R3, R4and R5are the same or different and are each hydrogen or lower alkyl; each R6is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R7is hydrogen, lower alkyl or lower alkenyl, X is oxy and thio, Y is carbonyl, —(CH2)1-3—, —(C1-C3)alkyl(CO)—, or —(CH2)1-3SO2—; Z is hydroxy, lower alkoxy, (C2-C4)acyloxy, —N(R8)(R9), phenylamino, (ω-(4-pyridyl)(C2-C4alkoxy), (ω-((R8)(R9)amino)(C2-C4alkoxy), an amino acid ester of (ω-(HO)(C2-C4))alkoxy, —N(R8)CH(R8)CO2H, 1′-D-glucuronyloxy, —SO3H, —PO4H2, —N(NO)(OH), —SO2NH2, —PO(OH)(NH2), —OCH2CH2N(CH3)3+, or tetrazolyl; wherein R8and R9are each H, (C1-C3)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R8), S or nonperoxide O; n is 0, 1, 2, or 3; wherein R8and R9are each H, (C1-C3)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R8), S or nonperoxide O; each alkyl or phenyl group of R1, R2, R3, R4, R5, R6, R7and Z is optionally substituted with 1, 2, or 3 (C1-C4)alkyl groups; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 3053255 (1962-09-01), Meyer
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 3843480 (1974-10-01), Dreher
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 3948254 (1976-04-01), Zaffaroni
patent: 3948262 (1976-04-01), Zaffaroni
patent: 3974179 (1976-08-01), Demerson et al.
patent: 3993073 (1976-11-01), Zaffaroni
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4310509 (1982-01-01), Berglund et al.
patent: 4337760 (1982-07-01), Rubin
patent: 4460562 (1984-07-01), Keith et al.
patent: 4466953 (1984-08-01), Keith et al.
patent: 4482534 (1984-11-01), Blank
patent: 4485097 (1984-11-01), Bell
patent: 4505891 (1985-03-01), Ito
patent: 4533540 (1985-08-01), Blank
patent: 4542012 (1985-09-01), Dell
patent: 4542013 (1985-09-01), Keith
patent: 4560555 (1985-12-01), Snider
patent: 4585877 (1986-04-01), Demerson et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4608249 (1986-08-01), Otsuka et al.
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 4806356 (1989-02-01), Shaw
patent: 4940587 (1990-07-01), Jenkins et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5599946 (1997-02-01), Vincenzo et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5780435 (1998-07-01), Garnick et al.
patent: 5811558 (1998-09-01), Adger et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5968974 (1999-10-01), Kargman et al.
patent: 6066741 (2000-05-01), Vigano' et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6300313 (2001-10-01), Engel et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 2003/0004142 (2003-01-01), Prior et al.
patent: 2003/0004143 (2003-01-01), Prior et al.
patent: 2005/0239752 (2005-10-01), Carson et al.
patent: 1299577 (1992-04-01), None
patent: 2226340 (1973-03-01), None
patent: 0289262 (1986-11-01), None
patent: 1436893 (1976-05-01), None
patent: WO-96/28148 (1996-09-01), None
patent: WO-9748391 (1997-12-01), None
patent: WO-98/09603 (1998-03-01), None
patent: WO-98/18490 (1998-05-01), None
patent: WO-98/40078 (1998-09-01), None
patent: WO-00/02555 (2000-01-01), None
patent: WO-00/13410 (2000-03-01), None
patent: WO-0106990 (2001-02-01), None
patent: WO-02/02125 (2002-01-01), None
patent: WO-0212188 (2002-02-01), None
Abramson, S. B., et al.; “The Mechanisms of Action of Nonsteroidal Antiimflammatory Drugs”,Arthritis&Rheumatism, 32 (1), (Jan. 1989), 1-9.
Alexanian, R., et al., “The Treatment of Multiple Myeloma”,The New England Journal of Medicine, 330 (7), (Feb. 17, 1994), 484-489.
Barlogie, B., et al., “Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.”,Blood, 72, (1988), 2015-2019.
Bataille, R., et al., “Multiple Myeloma”,New England Journal of Medicine, 336, (1997), 1657-1664.
Becker-Scharfenkamp, U., et al., “Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography”,Journal of Chromatography, 621 (2), (Nov. 24, 1993), 199-207.
Bellosillo, B., “Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells”,Blood, 92 (4), (Aug. 15, 1998), 1406-1414.
Berendes, U., et al., “Simultaneous Determination of the Phase II Metabolites of the Non Steriodal Anti-inflammatory Drug Etodolac in Human Urine”,Enantiomer, 1, Abstract Only, Chemical Abstracts, Abstract No. 126:207064q,(1996), 415-422.
Brenna, E., et al., “New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron, 53, 17769-17780.
Brocks, D. R., et al., “Etodolac Clinical Pharmacokinetics”,Clinical Pharmacokinetics, 26, (4), (1994), 259-274.
Carson, D. A., et al., “Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine”,Proc. Natl. Acad. Sci. USA, 89 (7), (Apr. 1992), 2970-2974.
Chinetti, G., et al., “Activation of Proliferator-activated Receptors alpha and Y Induces Apoptosis of Human Monocyte-derived Macrophages”,The Journal of Biological Chemistry, 273 (40), (Oct 2, 1998), 25573-25580.
Cunningham, D. et al., “High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data”,Journal of Clinical Oncology, 12, (1994), 764-768.
Demerson, C. A., et al., “Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids”,Journal of Medicinal Chemistry, 19 (3), (1976), 391-395.
Demerson, C. A., et al., “Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers”,J. Med. Chem., 26 (12), (Dec. 1983), 1778-1780.
Drachenberg, D. F., et al., “Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation”,Seminars in Surgical Oncology, 18 (1), (Jan./Feb. 2000), 37-44.
Duffy, C. P., et al., “Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)”,European Journal of Cancer, 34 (8), (Jul. 1998), 1250-1259.
Hahnfeld, L. E., et al., “Prostate Cancer”,The Medical Clinics of North America—The Aging Male Patient, 83 (5), (Sep. 1999), 1231-1245.
Harousseau, J. L., et al., “Double-Intensive Therapy in High-Risk Multiple Myeloma”,Blood, 79 (11), (Jun. 1, 1992), 2827-2833.
Krajewski, S., et al., “Detection of Multiple Antigens on Western Blots”,Analytical Biochemistry, 236 (2), Article No. 0160,(May 1996), 221-228.
Landis, S. H., et al., “Cancer Statistics, 1998”,CA Cancer J. Clin., 48 (1), (1998), 6-29.
Lee, D. H., et al., “Proteasome Inhibitors: Valuable New Tools For Cell Biologists”,Trends in Cell Biology, 8, (Oct. 1998), 397-403.
Lehmann, J. M., et al., “Peroxisome Proliferator-activated Receptors alpha and Y Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs”,The Journal of
Carson Dennis A.
Corr Mary Patricia
Leoni Lorenzo M.
Cephalon Inc.
Lewis Amy
Marschel Ardin H.
Schwegman Lundberg Woessner & Kluth P.A.
The Regents of the University of California
LandOfFree
Use of etodolac to treat hyperplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of etodolac to treat hyperplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of etodolac to treat hyperplasia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3796035